Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Experience from the Argentine Pegvisomant Observational Study: preliminary data.

N García Basavilbaso, M Guitelman, A Nagelberg

Frontiers of Hormone Research

|July 10, 2010

Summary

Related Concept Videos

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Maternal stress and fetoplacental cortisol regulation in small-for-gestational-age newborns.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025

Same author

Hypersensitivity to lipoic acid.

European annals of allergy and clinical immunology·2023

Same author

Hair cortisol in polycystic ovary syndrome.

Scientific reports·2022

Same author

Evolution of echocardiographic and cardiac magnetic resonance imaging abnormalities during follow-up in patients with multisystem inflammatory syndrome in children.

European heart journal. Cardiovascular Imaging·2022

Same author

Fetal neurosonography at 31-35 weeks reveals altered cortical development in pre-eclampsia with and without small-for-gestational-age fetus.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2022

Same author

Self-rated health in individuals with and without disease is associated with multiple biomarkers representing multiple biological domains.

Scientific reports·2021

This summary is machine-generated.

Pegvisomant effectively controls acromegaly in patients resistant to other treatments. This study shows significant IGF-I normalization with manageable side effects, offering a valuable therapeutic option.

Area of Science:

Endocrinology
Pharmacology
Oncology

Background:

Acromegaly requires effective treatments for patients refractory to surgery and somatostatin analogs.
Pegvisomant, a growth hormone (GH) receptor antagonist, offers a therapeutic alternative.

Purpose of the Study:

To evaluate the long-term safety and efficacy of pegvisomant in acromegaly patients.
To establish the first pegvisomant treatment database in Argentina.

Main Methods:

Observational, multicenter study involving 28 acromegaly patients.
Review of medical records for patients treated with pegvisomant due to lack of response or intolerance to somatostatin analogs.

Main Results:

Biochemical control (normal IGF-I) achieved in 45% at 3 months and 58.8% at 6 months.

Related Experiment Videos

Mean daily pegvisomant dose was 9.6+/-1.1 mg.

Adverse events (21.4%) included injection site reactions and elevated liver enzymes; no tumor enlargement observed.

Conclusions:

Pegvisomant demonstrates efficacy in achieving biochemical control of acromegaly.
Long-term safety profile appears favorable with manageable adverse events.
This study provides crucial preliminary data on pegvisomant use in Argentina.